STOCK TITAN
  1. Home
  2. News
  3. PROK

ProKidney Corp - PROK STOCK NEWS

Welcome to our dedicated news page for ProKidney (Ticker: PROK), a resource for investors and traders seeking the latest updates and insights on ProKidney.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect ProKidney's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of ProKidney's position in the market.

News
ProKidney Announces Key Leadership Appointments Strengthening Clinical and Technical Operations
Rhea-AI Summary
ProKidney Corp. (PROK) announces strategic appointments of Dr. Ulrich Ernst as Executive Vice President of Technical Operations and Mr. Lucio Tozzi as Senior Vice President of Global Clinical Operations. Dr. Ernst brings 30 years of experience in process development and manufacturing of cell therapies, while Mr. Tozzi has extensive experience in clinical trial execution. Their expertise aims to enhance ProKidney's leadership team for the completion of Phase 3 program and future commercialization.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.86%
Tags
none
-
News
ProKidney Reports Full Year 2023 Financial Results and Recent Corporate Highlights
Rhea-AI Summary
ProKidney Corp. (PROK) releases financial results for 2023, showing significant revenue growth and positive clinical developments in CKD treatments.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.19%
Tags
earnings
-
News
ProKidney to Participate in Jefferies Biotech on the Bay Summit
Rhea-AI Summary
ProKidney Corp. to Participate in Jefferies Biotech on the Bay Summit, Focusing on Cellular Therapeutics for Chronic Kidney Disease
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.23%
Tags
conferences
News
ProKidney Appoints Nikhil Pereira-Kamath, MBA, as Chief Business Officer
Rhea-AI Summary
ProKidney Corp. (Nasdaq: PROK) appoints Nikhil Pereira-Kamath, MBA, as Chief Business Officer, leveraging his extensive experience in new business development and strategic partnerships from his role as former CEO of Africa Healthcare Network. Mr. Pereira-Kamath's global responsibility for commercial strategy and investor relations aims to drive the company's growth and potential commercialization of their lead program, REACT®.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10.16%
Tags
management
-
News
ProKidney to Participate in a Fireside Chat at the Upcoming Evercore ISI 6th Annual HEALTHCONx Conference
Rhea-AI Summary
ProKidney Corp. (PROK) to Participate in Fireside Chat at Evercore ISI HEALTHCONx Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.68%
Tags
conferences
-
News
ProKidney Reports Third Quarter Financial Results
Rhea-AI Summary
ProKidney Corp. (Nasdaq: PROK) announced its financial results for the third quarter of 2023, with $400 million in cash and plans to continue executing Phase 2 and Phase 3 trials in high-risk CKD patients. The company expects cash to fund operations into the fourth quarter of 2025 and to release interim data readouts for REGEN-007 during that period, remaining well capitalized to execute its development strategy.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5%
Tags
earnings
News
ProKidney Announces Positive Interim Data from RMCL-002 Phase 2 Clinical Trial of Renal Autologous Cell Therapy (REACT®) for Diabetic CKD and Provides Corporate Updates
Rhea-AI Summary
ProKidney Corp. (Nasdaq: PROK) announced updated positive interim diabetic CKD data from its RMCL-002 Phase 2 study, demonstrating the potential efficacy of REACT® to preserve kidney function in diabetic CKD patients. The company plans to focus its Phase 3 development program on patients with Stage 3b and 4 diabetic CKD at highest risk of advancing to kidney failure. Dr. Bruce Culleton appointed as ProKidney CEO and the company has sufficient capital to fund operations into fourth quarter 2025.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5%
Tags
clinical trial
-
News
ProKidney Announces Four Abstracts Selected for Presentation at the American Society of Nephrology’s Kidney Week 2023
Rhea-AI Summary
ProKidney Corp. will present four posters at the upcoming American Society of Nephrology's Kidney Week. The posters will discuss investigations into the mechanism of action and clinical outcomes observed with REACT®. ProKidney booth will also provide additional information on REACT®.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.55%
Tags
none
-
News
ProKidney to Participate in Fireside Chat at the Morgan Stanley Global Healthcare Conference
Rhea-AI Summary
ProKidney Corp. CEO to participate in fireside chat at Morgan Stanley Global Healthcare Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.5%
Tags
conferences
News
ProKidney Reports Second Quarter Financial Results and Recent Corporate Highlights
Rhea-AI Summary
ProKidney Corp. announces financial results for Q2 2023, advances REACT development programs, and purchases facility in Greensboro. Cash and marketable securities total $446.1 million. R&D expenses increase to $26.4 million. G&A expenses increase to $13.5 million. Net loss before noncontrolling interest is $34.8 million.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.73%
Tags
earnings
Stock PROK logo
ProKidney Corp

Nasdaq:PROK

PROK Rankings

#3967 Ranked by Market Cap
#5395 Ranked by Stock Gains
N/A Ranked by Dividends

PROK Stock Data

1.80B
43.48M
23.14%
60.71%
22.69%
Research and Development in Biotechnology
Professional, Scientific, and Technical Services
Link
United States
Winston-Salem

About PROK

prokidney (nasdaq: prok), a pioneer in the treatment of ckd through innovations in cellular therapy, was founded in 2015 after a decade of research. prokidney’s lead product candidate, react™ (renal autologous cell therapy), is a first-of-its-kind, patented disease-modifying autologous cellular therapy with the potential to not only slow and stabilize the progression of ckd, but in some cases potentially drive meaningful improvement in kidney function. late-stage ckd, stage 3b - 4, is a key target for react™ therapy. react™ has received regenerative medicine advanced therapy (rmat) designation, as well as fda and ema guidance, supporting its ongoing phase 3 clinical program, which launched in january 2022. for more information, visit www.prokidney.com.